Neha Vapiwala, MD, on Highlights in Prostate Cancer From ASCO GU 2026
2026 ASCO GU
Neha Vapiwala, MD, of the University of Pennsylvania, discusses key themes in prostate cancer data presented at this year’s symposium, including personalization of therapy, treatment sequencing considerations, the role of radiopharmaceuticals, long-term radiotherapy results, using AI and associated tools in the clinic, survivorship, and managing quality of life.
Abstracts Mentioned:
EORTC 1333/PEACE-3
ASCENDE-RT
Abstract 215
Abstract 362
Abstract 305
The ASCO Post Staff
Thomas Powles, MD, PhD, FCRP, of Barts Cancer Centre, Queen Mary University of London, shares findings from the phase II RC48G001 trial of disitamab vedotin, an antibody-drug conjugate comprising a novel anti-HER2 antibody, disitamab, and an MMAE payload. The agent demonstrated “promising antitumor activity and a manageable safety profile, consistent with results from China, supporting further evaluation,” concluded investigators (Abstract LBA631).
The ASCO Post Staff
Amar Kishan, MD, University of California, Los Angeles, discusses results from an individual patient data meta-analysis of randomized trials to quantify the benefit of adding hormone therapy to postoperative radiotherapy in patients with localized prostate cancer after radical prostatectomy (Abstract 305).
Click here to read The Lancet publication.
The ASCO Post Staff
Maha H.A. Hussain, MD, FASCO, FACP, of the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, reviews results from the BRCAAway trial, which evaluated the efficacy of abiraterone vs olaparib vs the two agents in combination as first-line therapy for patients with metastatic castration-resistant prostate cancer harboring germline or somatic homologous recombination repair mutations. Progression-free survival results were previously reported; the data presented at this year’s meeting focused on overall survival (Abstract 16).
The ASCO Post Staff
Enrique Gallardo, MD, of Parc Taulí University Hospital, presents final overall survival results from the EORTC 1333/PEACE-3 trial, which is a phase III trial evaluating the addition of radium-223 to enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases. Earlier data from the trial showed that the combination prolonged both radiographic progression–free and overall survival; the new data include a final overall survival analysis and updated safety results (Abstract 15).
The ASCO Post Staff
Scott Tyldesley, MD, FRCPC, of BC Cancer Vancouver, reports on the 15-year survival analysis from the ASCENDE-RT trial, which randomly assigned patients to receive either prostate brachytherapy or the external-beam radiotherapy boost; both arms also received androgen-deprivation therapy. Fifteen-year overall survival and cumulative risk of death from prostate cancer were analyzed (Abstract 306).
